Shawn P Zinnen

Title: The Innovations of Shawn P. Zinnen

Introduction

Shawn P. Zinnen is an innovative inventor based in the United States. He has made significant contributions to the field of medicine and pharmaceuticals. His work focuses on developing stable dosage forms for antitumor preparations, which are crucial for effective treatment.

Latest Patents

Shawn P. Zinnen holds a patent for a "Stable Dosage Form Of Etidronate-Cytarabine Conjugate, And Use Thereof." This invention relates to a novel dosage form that ensures the hydrolytic and physical stability of an antitumor preparation. The stable dosage form is a lyophilisate comprising an etidronate-cytarabine conjugate or a pharmaceutically acceptable salt thereof, along with a stabilizer that is a divalent metal salt. The molar ratio of stabilizer to conjugate ranges from 1:1 to 20:1. This formulation guarantees the stability of the conjugate during long-term storage and ensures the stability of solutions for parenteral administration during clinical use.

Career Highlights

Shawn P. Zinnen is currently associated with Maxwell Biotech Group Ltd., where he continues to advance his research in pharmaceuticals. His work is pivotal in developing new treatment options for patients suffering from various conditions.

Collaborations

Shawn collaborates with notable colleagues, including Ekaterina Alekseevna Ivanova and Alexander Karpeisky. Their combined expertise contributes to the innovative projects at Maxwell Biotech Group Ltd.

Conclusion

Shawn P. Zinnen's contributions to the field of pharmaceuticals highlight the importance of innovation in medicine. His work on stable dosage forms is a testament to his commitment to improving patient care through scientific advancements.